drugset / Trial / NCT01469559

Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy

NCT01469559

Phase 2 Completed 12 enrolled University of Calgary
RandomizedParallel-groupTriple-blindPrevention

Summary

The aim of this study is to evaluate the safety and tolerability of intranasal insulin in people with type 1 diabetes and diabetic peripheral neuropathy and to determine whether intranasal insulin is effective in slowing the progression of diabetic neuropathy.

Timeline

Start
2011-08
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic 80 iu Intranasal